REFERENCES
- Caine M. The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy. J Urol 1986; 136: 1–4.
- Caine M, Perlberg S, Shapiro A. Phenoxybenzamine for benign prostatic obstruction. Review of 200 cases. Urol 1981; 17: 542–546.
- Cavero I, Hicks P, Langer S et al. Cardiovascular synergistic action between diltiazem and alfuzosin under in vivo and in vitro conditions. Proceedings of the British Pharmacological Society. Southampton. Bt J Pharmcol 1985; 84 (Suppl.) 16.
- Donnelly R, Meredith P, Elliott H. Pharmacokinetic-pharmacodynamic relationships of alpha-adrenoceptor antagonists. Clin Pharmacokinet 1989; 17: 264–274.
- Fabricius PG, Weizert P, Dunzendorfer U, Hannaford JM, Maurath C. Efficacy of one-a-day terazosin in benign prostatic hyperplasia: A randomized, double-blind placebo-controlled clinical trial. The Prostate 1990; (Suppl. 3): 85–93.
- Hedlund H, Andersson KE, Ek A. Effects of prazosin in patients with benign prostatic obstruction. J Urol 1983; 130: 275–278.
- Lepor H, Gup DI, Baumann M, Shapiro E. Laboratory assessment of terazosin and a-l-blockade in prostatic hyperplasia. Urology 1988; (Suppl.) vol 32, 6: 21–26.
- Lepor H. Alpha adrenergic antagonists for the treatment of symptomatic BPH. Int J of Clin Pharm Ther and Tox 1989; 27: 151–155.
- Ramsay JWA, Scott GI, Whitfield HN. A double-blind controlled trial of a new a-l blocking drug in the treatment of bladder outflow obstruction. Br J Urol 1985; 57: 657–659.